-
Atezolizumab approved as first-line therapy for chemotherapy-ineligible bladder cancer patients
Atezolizumab’s third approval in the last year provides an important treatment option for a neglected population of…
-
TIME Magazine Names CRI’s Dr. James Allison One of 100 Most Influential People
TIME magazine honors Dr. Allison’s development of the first checkpoint immunotherapy, which has led to a revolution…
-
AACR17 Update: Checkpoint Immunotherapy Clinical Trials in Melanoma and Lung Cancer
In-depth analysis of long-term clinical trial data provides important insights for doctors treating…
-
AACR17 Update: Checkpoints, Vaccines, and the Power of Prediction
Day 3 at AACR17 highlighted the importance of immune memory and personalized approaches…
-
AACR17 Update: CAR T Cells, Regulatory T Cells, and the Future of Immunotherapy
Day two addressed several strategies to improve immunotherapy’s precision and effectiveness
-
AACR17 Update: Taking Immunotherapy to the Next Level
After cancer immunotherapy’s initial successes, new challenges are being confronted
-
AACR17: Immunotherapy’s Impact on the Future of Cancer Treatment
Dozens of CRI scientists to highlight the latest immunotherapy breakthroughs during five-day conference in nation’s capital.
-
Pembrolizumab Approved for Children and Adults with Hard-to-Treat Hodgkin Lymphoma
Pembrolizumab is second anti-PD-1 drug approved for adults with cHL, first for any childhood cancer
-
Colorectal Cancer Awareness Month: How Immunotherapy Offers Hope for the Future
March is Colorectal Cancer Awareness Month, and the need for a spotlight on this disease is as…
